Trending...
- Naperville Police Host College Safety Webinar for Students and Parents on July 31
- Open Appeal: Renew Indian Passports by Citizenship, Not Immigration Status
- AF 5.0: Why AF5.0 Is Becoming a Core Platform for Quantitative Education
CHICAGO, June 22, 2025 ~ A recent study has revealed that oral semaglutide, a medication used to treat type 2 diabetes, can significantly reduce the risk of cardiovascular events by 14%. The results were presented at the American Diabetes Association's® (ADA) 85th Scientific Sessions in Chicago as a late-breaking symposium.
The study, known as the Semaglutide Cardiovascular Outcomes Trial (SOUL), focused on adults with type 2 diabetes who are at a higher risk for cardiovascular disease. It is well-known that individuals with diabetes have a 2-4 times increased risk of developing heart disease compared to those without diabetes. This risk increases with poor glycemic control and can lead to serious conditions such as heart attacks, stroke, and heart failure.
One of the major benefits of oral semaglutide is that it eliminates the need for injections, making it more convenient for patients and potentially improving adherence to treatment. This could also lead to earlier initiation of therapy and provide cardiovascular protection for patients who may have been hesitant to use injectable medications.
More on illi News
The double-blind, placebo-controlled trial included 9,650 participants aged 50 or older with type 2 diabetes and an A1C level between 6.5% and 10.0%. All participants had either known atherosclerotic cardiovascular disease or chronic kidney disease, or both. They were randomly assigned to receive either once-daily oral semaglutide or a placebo in addition to standard care.
The primary outcome of the study was major adverse cardiovascular events (MACE), which includes death from cardiovascular causes, nonfatal myocardial infarction (heart attack), or nonfatal stroke. The results showed that there was a significant reduction in MACE among those taking oral semaglutide compared to those taking the placebo. The incidence of serious adverse events was similar between the two groups.
Dr. Darren K. McGuire, lead author of the study and a professor of medicine at UT Southwestern Medical Center, emphasized the importance of addressing co-morbidities such as heart disease when treating patients with type 2 diabetes. He believes that the findings of this study suggest that oral semaglutide could be a promising option for patients in need of treatment for both diabetes and cardiovascular risk.
More on illi News
The initial results of the study were published in the New England Journal of Medicine in March, showing a 14% reduction in MACE. The new results presented at the ADA's Scientific Sessions will provide further insight into these findings.
Dr. McGuire will present the full results during a symposium presentation on Sunday, June 22 at 4:30 PM CT. The presentation is titled "Effects of Oral Semaglutide on Cardiovascular (and Other) Outcomes in People with Type 2 Diabetes at High CV Risk." The researchers also plan to implement these findings in a real-world setting to better inform clinical next steps.
This study highlights the potential benefits of oral semaglutide for individuals with type 2 diabetes who are at high risk for cardiovascular disease. It offers hope for improved outcomes and better management of this chronic condition.
The study, known as the Semaglutide Cardiovascular Outcomes Trial (SOUL), focused on adults with type 2 diabetes who are at a higher risk for cardiovascular disease. It is well-known that individuals with diabetes have a 2-4 times increased risk of developing heart disease compared to those without diabetes. This risk increases with poor glycemic control and can lead to serious conditions such as heart attacks, stroke, and heart failure.
One of the major benefits of oral semaglutide is that it eliminates the need for injections, making it more convenient for patients and potentially improving adherence to treatment. This could also lead to earlier initiation of therapy and provide cardiovascular protection for patients who may have been hesitant to use injectable medications.
More on illi News
- Bent Danholm To Be Featured On Global Podcast Network In Live Interview
- AdvoCast Expands Leadership in Strategic Comms with New Role Producing "Communication Breakdown" Podcast
- InventHelp Inventor Develops Wearable Tracking Device (CHK-2215)
- Naperville: Structure Fire in the 1000 Block of Frances Court
- Rocket.Chat assessed "Awardable" for Department of Defense work in the CDAO's Tradewinds Solutions Marketplace
The double-blind, placebo-controlled trial included 9,650 participants aged 50 or older with type 2 diabetes and an A1C level between 6.5% and 10.0%. All participants had either known atherosclerotic cardiovascular disease or chronic kidney disease, or both. They were randomly assigned to receive either once-daily oral semaglutide or a placebo in addition to standard care.
The primary outcome of the study was major adverse cardiovascular events (MACE), which includes death from cardiovascular causes, nonfatal myocardial infarction (heart attack), or nonfatal stroke. The results showed that there was a significant reduction in MACE among those taking oral semaglutide compared to those taking the placebo. The incidence of serious adverse events was similar between the two groups.
Dr. Darren K. McGuire, lead author of the study and a professor of medicine at UT Southwestern Medical Center, emphasized the importance of addressing co-morbidities such as heart disease when treating patients with type 2 diabetes. He believes that the findings of this study suggest that oral semaglutide could be a promising option for patients in need of treatment for both diabetes and cardiovascular risk.
More on illi News
- Suburban Orthopaedics Expands Foot and Ankle Team with Fellowship-Trained Surgeon Shoueb Malik, DPM
- Rising Home Values Aren't Preventing Foreclosures
- Success for Global Communications Leader IQSTEL, Inc. Growing From $13 Million Revenue in 2018 to Nearly $300 Million Last Year
- Designer Creates 100 Free Posters for Black Business Month
- Artbound: "The Cheech" Awarded Two 2025 LA Area EMMY Awards — Honored in ARTS & MUSIC COMPOSITION
The initial results of the study were published in the New England Journal of Medicine in March, showing a 14% reduction in MACE. The new results presented at the ADA's Scientific Sessions will provide further insight into these findings.
Dr. McGuire will present the full results during a symposium presentation on Sunday, June 22 at 4:30 PM CT. The presentation is titled "Effects of Oral Semaglutide on Cardiovascular (and Other) Outcomes in People with Type 2 Diabetes at High CV Risk." The researchers also plan to implement these findings in a real-world setting to better inform clinical next steps.
This study highlights the potential benefits of oral semaglutide for individuals with type 2 diabetes who are at high risk for cardiovascular disease. It offers hope for improved outcomes and better management of this chronic condition.
Filed Under: Business
0 Comments
Latest on illi News
- Private Autopsies Provide Families in Colorado with Answers and Closure
- Vijay Tirathrai named Managing Director in Dubai, UAE
- How smart women use BAY Miner cloud mining to easily earn Bitcoin every day
- Qualis LLC Appoints Jeremy Mallicoat as Chief Financial Officer to Advance Growth and Acquisition Strategy
- Bynn Intelligence Reinvents Document Fraud Detection with Groundbreaking Acquisition and Revolutionary AI Model
- Mentor Agile Says WIOA‑Funded Seats Still Available for Summer Product‑Owner
- 2A Commerce Launches Firearms eCommerce Platform
- GOAT SKIN® Launches the Campaign Tee: A Sovereign Statement in Luxury Apparel
- Midwest Pond Features & Landscape Says "We're Ready for Repairs"
- Brianne Zitko Named Winner of 2025 Great Companies International Women Entrepreneur Award
- 4Closure Rescue Expands Foreclosure Support Services to Underserved Communities Across the U.S
- Premier Protein® and Milk Bar® Launch New "Power Hour" Protein Menu
- Exposing Psychiatric Abuse, CCHR Has Pushed for Global Human Rights Protections
- Spur Chicago Builds Momentum Through Summer Field Collaborations
- RDG Mining launches 1-day XRP、BTC mining contract, XRP short-term investment users surge 500%
- Donna Cardellino and Paul Lafrance Sign Exclusive Deal for Worldwide Expansion into Commercial and Luxury Real Estate Design Projects
- New Book "Three Permissions" Redefines Self-Leadership for a Burnout-Weary Culture
- Opening a new era of USDC smart cloud mining: CJB Crypto makes digital dollar earnings within reach
- The Evolution of the BDCV Platform: Empowering Mental Health & Wellness
- DFS Fullcolor Printing by Inkdnylon | Nationwide Print Partner